Detalles de la búsqueda
1.
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.
Front Oncol
; 14: 1326715, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38711854
2.
Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Clin J Oncol Nurs
; 25(2): E1-E9, 2021 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739346
3.
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
PLoS One
; 16(6): e0253021, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34153052
4.
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
PLoS One
; 16(12): e0262326, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34972194
5.
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
J Clin Oncol
; 39(28): 3140-3148, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34428076
Resultados
1 -
5
de 5
1
Próxima >
>>